Last Thursday at Genesis in London, I had the chance to meet with Eva-Lotta Allan, CBO of Immunocore (and previously from Ablynx). After a last-minute confirmation before the event, we came to meet and it helped me understand why Immunocore could be the next Biotech success-story in Europe…
I’m sure you’ve heard of Immunocore this year. This Oxford-based Biotech company is developing TCR-based immuno-oncology treatments and has raised nearly €300M ($320M) in its last round of fundraising – a pure anomaly for the European standard.
Even worldwide, this is the second private biggest fundraising ever for a Biotech company after Boston-based Moderna (my exclusive interview of the CEO here).
After being in London, I did a stop in Paris and talked with a friend at the VC Edmond de Rothschild. He told me they were impressed by the company:
“Immunocore could become the next Amgen“.